StockNews.com started coverage on shares of Voyager Therapeutics (NASDAQ:VYGR – Get Rating) in a report published on Thursday morning. The brokerage issued a buy rating on the stock.
Separately, Oppenheimer began coverage on shares of Voyager Therapeutics in a report on Thursday, March 9th. They issued an outperform rating and a $14.00 price target for the company.
Voyager Therapeutics Stock Performance
Voyager Therapeutics stock opened at $7.92 on Thursday. The company has a 50-day simple moving average of $8.22 and a 200-day simple moving average of $6.70. Voyager Therapeutics has a one year low of $4.61 and a one year high of $10.81.
Insider Transactions at Voyager Therapeutics
Institutional Trading of Voyager Therapeutics
Hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC lifted its position in shares of Voyager Therapeutics by 32.4% in the third quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after purchasing an additional 832,000 shares in the last quarter. Hillsdale Investment Management Inc. raised its position in Voyager Therapeutics by 347.3% during the third quarter. Hillsdale Investment Management Inc. now owns 87,967 shares of the company’s stock valued at $521,000 after acquiring an additional 68,300 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its position in Voyager Therapeutics by 11.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 37,788 shares of the company’s stock valued at $224,000 after acquiring an additional 3,933 shares in the last quarter. Bailard Inc. bought a new position in Voyager Therapeutics during the third quarter valued at approximately $171,000. Finally, Gamco Investors INC. ET AL bought a new position in Voyager Therapeutics during the fourth quarter valued at approximately $73,000. 59.58% of the stock is owned by hedge funds and other institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.
- Get a free copy of the StockNews.com research report on Voyager Therapeutics (VYGR)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.